How Bristol Myers Squibb Beat Wall Street Estimates in Q3

Bristol Myers Squibb (NYSE:BMY) hasn't been a big winner for investors so far this year. And that's despite the big drugmaker having some pretty good news along the way, including positive results from a late-stage study of experimental psoriasis drug deucravacitinib earlier this week.

The company had even more good news when it announced its third-quarter results before the market opened on Thursday. Here are the highlights of Bristol Myers Squibb's Q3 update.